Abstract

MORA, Claudia et al. Role of Anti-chromatin, anti-C1q and cell bound complement activation products in the early diagnosis of Systemic Lupus Erythematosus disease activity. Rev.Colomb.Reumatol. [online]. 2014, vol.21, n.2, pp.76-83. ISSN 0121-8123.

There is a need for the identification and validation of biomarkers that reflect the early onset of lupus activity or may be predictors of this. The clinical activity of systemic lupus erythematosus (SLE) fluctuates over time and the underlying activity leads to persistent tissue damage. This damage is a reflection of irreversible changes in the function and organic structure, so prevention, rather than treatment, should be the goal of any therapy in SLE.This will reduce morbidity, mortality, direct and indirect costs caused by the disease. It is necessary to find biomarkers of lupus activity that not only allow making treatment decisions in the short term, but also to correlate with clinical outcomes. These could also be useful in clinical trials and may shorten the duration of these studies. This article aims to find evidence on new biomarkers for SLE disease activity, and their current and future use. Emphasis will be made on the need to find new molecules for an early diagnosis of disease activity.

Keywords : Lupus erythematosus; Systemic Biological markers; Antibodies; Complement C4d; Complement C1q; Nucleosomes.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )